Eyebright Medical Technology Beijing Co Ltd (688050) - Net Assets
Based on the latest financial reports, Eyebright Medical Technology Beijing Co Ltd (688050) has net assets worth CN¥3.01 Billion CNY (≈ $440.17 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.90 Billion ≈ $571.13 Million USD) and total liabilities (CN¥894.96 Million ≈ $130.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Eyebright Medical Technology Beijing Co (688050) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.01 Billion |
| % of Total Assets | 77.07% |
| Annual Growth Rate | 39.14% |
| 5-Year Change | 70.21% |
| 10-Year Change | N/A |
| Growth Volatility | 64.05 |
Eyebright Medical Technology Beijing Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Eyebright Medical Technology Beijing Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Eyebright Medical Technology Beijing Co 's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Eyebright Medical Technology Beijing Co Ltd (2016–2024)
The table below shows the annual net assets of Eyebright Medical Technology Beijing Co Ltd from 2016 to 2024. For live valuation and market cap data, see Eyebright Medical Technology Beijing Co stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.63 Billion ≈ $385.47 Million |
+11.81% |
| 2023-12-31 | CN¥2.36 Billion ≈ $344.75 Million |
+22.70% |
| 2022-12-31 | CN¥1.92 Billion ≈ $280.98 Million |
+10.34% |
| 2021-12-31 | CN¥1.74 Billion ≈ $254.64 Million |
+12.44% |
| 2020-12-31 | CN¥1.55 Billion ≈ $226.47 Million |
+139.01% |
| 2019-12-31 | CN¥647.52 Million ≈ $94.75 Million |
+16.91% |
| 2018-12-31 | CN¥553.87 Million ≈ $81.05 Million |
+179.10% |
| 2017-12-31 | CN¥198.44 Million ≈ $29.04 Million |
+5.83% |
| 2016-12-31 | CN¥187.52 Million ≈ $27.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eyebright Medical Technology Beijing Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 97509203976.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥949.50 Million | 39.41% |
| Common Stock | CN¥189.54 Million | 7.87% |
| Other Comprehensive Income | CN¥182.45 Million | 7.57% |
| Other Components | CN¥1.09 Billion | 45.15% |
| Total Equity | CN¥2.41 Billion | 100.00% |
Eyebright Medical Technology Beijing Co Ltd Competitors by Market Cap
The table below lists competitors of Eyebright Medical Technology Beijing Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telecom Argentina S.A
F:TEO
|
$1.45 Billion |
|
Taiwan Fertilizer Co Ltd
TW:1722
|
$1.45 Billion |
|
Concentrix Corporation
NASDAQ:CNXC
|
$1.45 Billion |
|
Jiangsu Dagang Co Ltd
SHE:002077
|
$1.45 Billion |
|
Jiangsu Rongtai Industry Co. Ltd.
SHG:605133
|
$1.45 Billion |
|
Huafa Industrial Co Ltd Zhuhai
SHG:600325
|
$1.45 Billion |
|
Uwc Bhd
KLSE:5292
|
$1.45 Billion |
|
FLEX LNG Ltd
OL:FLNG
|
$1.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eyebright Medical Technology Beijing Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,129,634,577 to 2,409,498,353, a change of 279,863,776 (13.1%).
- Net income of 388,402,957 contributed positively to equity growth.
- Dividend payments of 70,558,404 reduced retained earnings.
- Share repurchases of 20,043,605 reduced equity.
- Other comprehensive income increased equity by 182,445,575.
- Other factors decreased equity by 200,382,747.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥388.40 Million | +16.12% |
| Dividends Paid | CN¥70.56 Million | -2.93% |
| Share Repurchases | CN¥20.04 Million | -0.83% |
| Other Comprehensive Income | CN¥182.45 Million | +7.57% |
| Other Changes | CN¥-200.38 Million | -8.32% |
| Total Change | CN¥- | 13.14% |
Book Value vs Market Value Analysis
This analysis compares Eyebright Medical Technology Beijing Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.06x to 4.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥2.68 | CN¥51.11 | x |
| 2017-12-31 | CN¥1.61 | CN¥51.11 | x |
| 2018-12-31 | CN¥4.22 | CN¥51.11 | x |
| 2019-12-31 | CN¥4.37 | CN¥51.11 | x |
| 2020-12-31 | CN¥9.43 | CN¥51.11 | x |
| 2021-12-31 | CN¥8.85 | CN¥51.11 | x |
| 2022-12-31 | CN¥9.82 | CN¥51.11 | x |
| 2023-12-31 | CN¥11.21 | CN¥51.11 | x |
| 2024-12-31 | CN¥12.72 | CN¥51.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eyebright Medical Technology Beijing Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.55%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.45x
- Recent ROE (16.12%) is above the historical average (7.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -0.75% | -3.21% | 0.19x | 1.25x | CN¥-20.12 Million |
| 2017 | -2.07% | -5.49% | 0.27x | 1.39x | CN¥-23.95 Million |
| 2018 | 3.69% | 15.99% | 0.22x | 1.06x | CN¥-34.78 Million |
| 2019 | 10.80% | 34.16% | 0.28x | 1.11x | CN¥4.93 Million |
| 2020 | 6.36% | 35.36% | 0.17x | 1.08x | CN¥-55.25 Million |
| 2021 | 10.24% | 39.56% | 0.21x | 1.22x | CN¥3.96 Million |
| 2022 | 12.51% | 40.15% | 0.26x | 1.21x | CN¥46.68 Million |
| 2023 | 14.27% | 31.96% | 0.31x | 1.44x | CN¥91.01 Million |
| 2024 | 16.12% | 27.55% | 0.40x | 1.45x | CN¥147.45 Million |
Industry Comparison
This section compares Eyebright Medical Technology Beijing Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,585,373,438
- Average return on equity (ROE) among peers: 5.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eyebright Medical Technology Beijing Co Ltd (688050) | CN¥3.01 Billion | -0.75% | 0.30x | $1.45 Billion |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $1.79 Billion | 0.80% | 1.04x | $521.28 Million |
| Blue Sail Medical Co Ltd (002382) | $203.26 Million | 29.44% | 0.87x | $1.08 Billion |
| Andon Health Co Ltd (002432) | $1.54 Billion | 0.94% | 0.53x | $4.93 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $3.13 Billion | 12.99% | 0.84x | $1.34 Billion |
| Guangzhou Improve Med Instrument (300030) | $563.53 Million | 4.77% | 0.17x | $380.05 Million |
| QITIAN Technology Group Co Ltd (300061) | $1.16 Billion | -31.55% | 0.49x | $950.81 Million |
| Shanghai Tofflon Science Tech (300171) | $3.12 Billion | 2.26% | 0.50x | $1.47 Billion |
| Truking Technology Ltd (300358) | $2.32 Billion | 6.92% | 0.71x | $1.03 Billion |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.33 Billion | 15.49% | 0.52x | $782.31 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $694.06 Million | 12.68% | 0.39x | $2.51 Billion |
About Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for opht… Read more